The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be essential for a preventative HIV-1 vaccine, but this has not yet been achieved by immunization. In contrast, some HIV-1-infected individuals naturally mount bNAb responses during chronic infection, suggesting that years of maturation may be required for neutralization breadth [1] [2] [3] [4] [5] [6] . Recent studies have shown that viral diversification precedes the emergence of bNAbs, but the significance of this observation is unknown 7, 8 .
Here we delineate the key viral events that drove neutralization breadth within the CAP256-VRC26 family of 33 monoclonal antibodies (mAbs) isolated from a superinfected individual. First, we identified minority viral variants, termed bNAbinitiating envelopes, that were distinct from both of the transmitted/founder (T/F) viruses and that efficiently engaged the bNAb precursor. Second, deep sequencing revealed a pool of diverse epitope variants (immunotypes) that were preferentially neutralized by broader members of the antibody lineage. In contrast, a 'dead-end' antibody sublineage unable to neutralize these immunotypes showed limited evolution and failed to develop breadth. Thus, early viral escape at key antibody-virus contact sites selects for antibody sublineages that can tolerate these changes, thereby providing a mechanism for the generation of neutralization breadth within a developing antibody lineage.
The identification of bNAbs against genetically diverse viruses such as HIV-1 (ref. 9) , together with in-depth longitudinal evolutionary studies are providing key insights for vaccine design 7, 8, [10] [11] [12] . BNAbs to the variable regions 1 and 2 (V1V2) of the HIV-1 envelope (Env) are among the most prevalent and potent cross-reactive antibodies, but the virological events that allow for their elicitation and maturation remain unclear. We have previously described the CAP256-VRC26 mAb lineage, isolated from an HIV-1 subtype C-superinfected individual, which targets the V1V2 C-strand at the apex of the viral envelope glycoprotein (Fig. 1a) 7 . This lineage developed from a bNAb precursor or unmutated common ancestor (UCA) with a 35-amino acid heavy chain complementarity determining region 3 (CDRH3), and it acquired breadth through moderate levels of somatic hypermutation (SHM) 7 . To better define the complex viral populations responsible for eliciting these antibodies and driving their maturation, we performed next-generation sequencing (NGS) at 28 different time points over 4 years (with an average of 85,000 reads and 788 consensus sequences per time point). From 6-13 weeks, all sequences were closely related to the primary infecting virus (PI) ( Fig. 1b and Supplementary Fig. 1 ), but at 15 weeks, when superinfection (SU) occurred, there was a dramatic shift in viral populations, with SU-like viruses accounting for 99.8% of 3,228 consensus sequences ( Supplementary Fig. 2) . From 17 weeks, V1V2 sequences from the PI and SU viruses persisted, rapidly forming a PI-SU recombinant population, although PI-like viruses dominated briefly at 23 weeks, perhaps as a result of immune escape from earlier non-V1V2-directed neutralizing antibodies that preferentially neutralized SU-like viruses 13 . Notably, diversification in all three viral populations (PI, SU and recombinants) increased after the CAP256-VRC26 lineage was first detected in blood by NGS at 34 weeks ( Fig. 1b and Supplementary Fig. 3 ).
As residues 169 and 166 in the V1V2 C-strand form a crucial part of the CAP256-VRC26 bNAb epitope and are likely to be important in virus-mAb co-evolution, we focused on defining escape mutations at these positions. Residue 169 differed between the PI (169Q) and SU viruses (169K), with the majority of viral variants circulating after 23 weeks possessing a PI-derived 169Q mutation ( Fig. 1c and Supplementary Fig. 2 ). From 27 weeks onwards, the virus sampled 11 different amino acids at position 169, and variation was most pronounced at 42 weeks ( Fig. 1c) , shortly before the development of neutralization breadth. The major escape pathway from 42-119 weeks was a 169I mutation, and thereafter 169E dominated. Toggling was also observed at position 166 ( Fig. 1d) , although this occurred later, with the wild-type 166R immunotype Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies (present in both the PI and SU viruses) occurring in more than 98% of sequences until 53 weeks. At 59 weeks, the virus sampled four amino acids (166R, T, K or S), and thereafter 166K, followed by 166S, became prevalent. By 159 weeks, all viral sequences contained the mutually exclusive K169E or R166S mutations. As both the K169E and R166S mutations abrogate neutralization by the CAP256-VRC26 mAbs 7, 13 it is unclear why it took two years for these escape pathways to dominate despite their low-level presence early in the development of the CAP256-VRC26 family ( Supplementary Fig. 2) .
The CAP256-VRC26 UCA was unable to neutralize any of 196 HIV-1 isolates ( Supplementary Fig. 4 ), suggesting that Env variants able to engage this UCA may be rare. Because CAP256-VRC26 NGS transcripts were first detected in blood 19 weeks after superinfection ( Supplementary Fig. 3 ), we analyzed contemporaneous (34-week) viral sequences to identify a bNAb-initiating Env. Neutralization of the SU virus, but not the PI virus, by the CAP256-VRC26 UCA indicated that an SU-like variant elicited this lineage 7 . Although 8% (75/937) of V1V2 next-generation sequences at the 34-week time point were SU-like, none were identical to the SU virus ( Fig. 2a and Supplementary Fig. 5 ). Single-genome amplification was therefore used to isolate six functional 34-week Env clones, which differed from the SU virus by 2-8 amino acids in V1V2 and by up to 26 changes across the entire Env (Fig. 2b) . We observed evidence of early immune pressure, with three of six clones containing K169I or K169E mutations, and four of six clones deleting or shifting the glycan at residue 139 ( Fig. 2c) . As expected, the clones with 169I or 169E mutations were resistant to neutralization by the UCA; however, the three clones containing a wild-type 169K were 5-17-fold better neutralized than the SU virus ( Fig. 2d) . Thus, the 34-week viral variants that evolved from the CAP256 SU T/F virus (but differed from the T/F virus by at least 12 amino acids) provided a stronger stimulus for the CAP256-VRC26 lineage.
We next sought to define how this lineage matured to acquire neutralization breadth in the context of CAP256 viral diversification. A heavy chain phylogenetic tree of 33 isolated CAP256-VRC26 mAbs (12 previously described 7 and 21 recently isolated mAbs 14 ) and CAP256-VRC26 NGS transcripts from 34 to 206 weeks showed an early bifurcation 7 (Fig. 3a) . A small sublineage of 34-59-week sequences, including the CAP256-VRC26.01 and 0.24 mAbs, exhibited restricted evolution. A second larger sublineage, containing transcripts from all time points as well as most of the mAbs (Fig. 3a) , displayed extensive evolution, suggesting adaption in response to emerging viral escape mutations, such as K169T/I/Q/R and R166K ( Fig. 1c,d) . To test this hypothesis, we introduced these immunotypes into the SU virus and assayed them against 32 mAbs (CAP256-VRC26.20 does not neutralize SU and was excluded). The CAP256-VRC26.01 and 24 mAbs, from the smaller sublineage with limited breadth, both neutralized the SU virus at 0.04 µg/ml (Fig. 3b) . However, SU viruses containing the 166 or 169 immunotypes were either neutralization resistant or showed a >670-fold reduction in neutralization sensitivity (Fig. 3b) . Thus, the inability of mAbs in this dead-end sublineage to tolerate viral escape mutations was likely to be responsible for limiting their evolution and capacity to become broadly neutralizing.
Among the 30 CAP256-VRC26 mAbs from the evolving sublineage that showed a range of neutralization breadth (2-63%), the 169T, 169I or 169Q mutations abolished or reduced the activity of mAbs with limited breadth (Fig. 3c) Pl-like C-strand n = 862
SU-like C-strand n = 75 a b c 8% more pronounced for the R166K mutant, which was resistant to 16 out of 30 mAbs (Fig. 3c) , consistent with the selection of this immunotype during later stages of bNAb development (Fig. 1d) . However, six of the nine broadest mAbs were still able to neutralize this mutant at titers <1 µg/ml. With the exception of the K169R mutation, breadth was correlated with the ability to neutralize the 169 or 166 mutants ( Fig. 3c and Supplementary Fig. 6 ). Overall mAbs with limited neutralization breadth were most severely affected by variation at positions 169 and 166, whereas the broadest mAbs were able to tolerate these early viral escape mutations, thus providing a mechanism for the evolution of neutralization breadth within this lineage.
Because high levels of SHM are often required for HIV-1 broad neutralization 15, 16 , we investigated the relationship between SHM and neutralization breadth in the CAP256-VRC26 family (Fig. 4a) . As expected, the nine mAbs with >40% breadth were 17-22% mutated from the UCA; however, three 'off-track' mAbs with a similar level of npg SHM (17-21%) had only 2-6% breadth (Fig. 4a) . Therefore, as observed in several families of HIV-specific antibodies [17] [18] [19] [20] and influenzaspecific antibodies 21 , high levels of SHM in the CAP256-VRC26 lineage were not sufficient to confer breadth. To determine whether different viral variants drove the evolution of broad versus off-track mAbs, we tested both groups of mAbs against longitudinal CAP256 viruses (Fig. 4b) . Hierarchical clustering analysis of mAbs and viruses on the basis of their neutralization profiles showed a clear phenotypic separation between broad and off-track mAbs, with the latter neutralizing substantially fewer autologous viruses, but we could not attribute this to any genetic features of the mAbs. Both groups neutralized viruses with an SU-like C-strand, including the bNAb-initiating 34-week clones. All viruses neutralized by off-track antibodies were also sensitive to at least one broad mAb, suggesting that viral variants associated with the development of neutralization breadth also selected off-track mAbs. Indeed, clustering of broad and off-track mAbs within a single phylogenetic branch highlights the stochastic nature of mAb maturation toward breadth (Fig. 4c) .
In conclusion, we identified 34-week viral variants, which we have termed bNAb-initiating Envs, that effectively engaged the UCA of the CAP256-VRC26 V1V2 lineage. Although low-frequency viral escape mutations at 27-30 weeks may suggest that CAP256-VRC26 antibodies were present earlier, the 34-week Envs nonetheless represent optimal priming immunogens for this lineage. Identification of rare bNAbinitiating Envs is likely to be of particular importance for V1V2 bNAb precursors, which are derived from a pool of rare B cells with long CDRH3 regions 8, 18, [22] [23] [24] [25] [26] . Second, we have defined a new mechanism for how accumulating viral variants contribute to bNAb development. Thus, viral escape creates multiple immunotypes, and in parallel SHM generates antibodies with differential abilities to engage these epitope variants. Those antibody sublineages that are able to tolerate variability at key epitope contacts will develop breadth ( Fig. 4d) . We note, Figure 4 Viral variants that shaped the maturation of broad and off-track antibodies. (a) Relationship between neutralization breadth of CAP256-VRC26 mAbs (%, y axis) and mutations away from the UCA (%, x axis). Broad mAbs with >40% neutralization breadth, off-track mAbs with limited neutralization breadth (<6%) and dead-end mAbs are shown in red, turquoise and gray respectively. The remaining 19 mAbs are shown in black. (b) CAP256-VRC26 mAbs and longitudinal CAP256 viruses isolated between 6-59 weeks are hierarchically clustered by their neutralization profiles. Neutralization sensitivity is shown as a heat map with potency indicated in the key. The sequence alignment shows viral C-strand amino acid residues between positions 160-172 (HXB2 numbering), shaded to designate sequences that are PI derived (blue shading), PI-SU recombinants (purple shading) or SU derived (no shading). Off-track (turquoise) and broad (red) mAbs are clustered separately, whereas longitudinal viral variants are clustered by neutralization sensitivity, largely segregated on the basis of an SU-derived V1V2 C-strand. (c) A condensed heavy chain phylogenetic tree ( Fig. 3) with a single clade expanded to illustrate the phylogenetic relatedness of an off-track mAb (turquoise) to seven broad mAbs (red). (d) Schematic depicting how CAP256 viral evolution results in the engagement of the CAP256-VRC26 UCA (light gray) and the subsequent development of two distinct mAb sublineages. The sublineage with restricted evolution contains deadend mAbs (dark gray), which cannot tolerate viral escape mutations. The continually evolving sublineage contains bNAbs (red) and off-track mAbs (turquoise). Although both bNAbs and off-track mAbs have high levels of SHM, only the former mature to recognize multiple immunotypes, and thus acquire breadth.
npg however, that viral diversity may also limit the evolution of less-tolerant mAbs (dead-end sublineages), or it may divert maturation of mAbs toward strain specificity (off-track mAbs) ( Fig. 4d) . This process, which provides a framework for vaccine design (Supplementary Fig. 7) , is distinct from the multi-lineage cooperative pathway described for a CD4-binding site bNAb lineage 10 , highlighting the complex and varied pathways to breadth. Future immunization strategies should therefore aim to include bNAb-initiating Envs to prime bNAb precursor B cells, as well as rationally verified Env variants as sequential boosts to mature the response to neutralization breadth.
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